文献速递前列腺癌

丹麦全国研究:前列腺特异性抗原检测与前列腺癌相关结局

Prostate-specific antigen testing and prostate cancer-related outcomes: a Danish nationwide study.
PubMed 文献 · BJU Int · 2026-03-04

终生PSA检测累积发生率为84%,前列腺癌诊断12%,前列腺癌特异性死亡5.0%。

要点

  • 丹麦PSA检测率高且集中于老年男性,与限制性指南相悖。
  • 终生PSA检测累积发生率84%,前列腺癌诊断12%,特异死亡5.0%。
  • 首次PSA检测中位年龄60岁,诊断中位年龄72岁,死亡中位年龄84岁。

核心结论

  • 丹麦PSA检测率高且老年男性中普遍,尽管有限制性国家指南和针对全科医生的培训。
  • 研究结果支持重新讨论PSA检测的可及性以减少不必要检测的危害。

研究设计与样本

  • 采用年龄标化率(每10万男性)和Aalen-Johansen估计量(考虑延迟进入)计算100岁时累积发生率。

主要发现

  • 100岁时累积发生率:PSA检测84%(95%CI 84-84%),前列腺组织学检查20%(95%CI 20-20%),活检15%(95%CI 15-15%),前列腺癌诊断12%(95%CI 11-12%),前列腺癌特异性死亡5.0%(95%CI 5.0-5.1%)。
  • 首次PSA检测中位年龄60岁(IQR 52-67),前列腺组织学检查和活检中位年龄70岁(IQR 64-76),前列腺癌诊断中位年龄72岁(IQR 66-78),前列腺癌特异性死亡中位年龄84岁(IQR 78-89)。

临床怎么用

  • 提示在限制性指南下PSA检测仍广泛用于老年男性,需关注不必要检测的潜在危害。
  • 临床决策中应结合年龄和预期寿命权衡PSA检测的获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the prostate-specific antigen (PSA) testing and prostate cancer-related outcomes in a national, publicly funded healthcare setting, with recommendations against testing of asymptomatic men. SUBJECTS AND METHODS: All men born between 1920 and 1970, alive and residing in Denmark on 1 January 2014, were quarried in the national health registries. Age-standardised rates (ASR) per 100 000 men for men aged >50 years and cumulative incidence at 100 years by Aalen Johansen estimator with delayed entry were estimated for PSA testing, prostate histology, biopsy, prostate cancer diagnosis, and prostate cancer-specific death. RESULTS: Among 1 371 099 eligible men, the ASR of PSA testing in 2023 was 14 659 tests per 100 000 men (95% confidence interval [CI] 14 585-14 733), and 21 828 tests per 100 000 men (95% CI 21 646-22 111) in men aged 70-79 years. Cumulative incidence at 100 years of a PSA test was 84% (95% CI 84-84%), prostate histology 20% (95% CI 20-20%), biopsy 15% (95% CI 15-15%), prostate cancer diagnosis 12% (95% CI 11-12%), and prostate cancer-specific death 5.0% (95% CI 5.0-5.1%). The median (interquartile range [IQR]) age at initial PSA test was 60 (52-67) years, 70 (64-76) years at prostate histology and biopsy, 72 (66-78) years at prostate cancer diagnosis, and 84 (78-89) years at prostate cancer-specific death. CONCLUSIONS: In Denmark PSA testing rates are high and prevalent in older ages, despite restrictive national guidelines and active training against PSA testing for general practitioners. The findings support the discussion of whether the availability of the PSA test should be reconsidered to minimise the harms associated with unnecessary testing.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Palshof FK, Mørch LS, Brasso K, et al. Prostate-specific antigen testing and prostate cancer-related outcomes: a Danish nationwide study. BJU Int. 2026. PMID: 41782199. doi:10.1111/bju.70208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。